PTAB/USPTO Update - November 2021

PTAB/USPTO Update - November 2021

Client Alert

Authors

USPTO News

Legislation

Notices, Guidance, and Requests

Final Rules

Interim Rules

  • There are no interim rules.

Proposed Rules

  • There are no proposed rules.

PTAB Decisions

  • New Precedential PTAB Decisions
    • There are no new informative PTAB decisions.
  • New Informative PTAB Decisions
    • There are no new informative PTAB decisions.

New Requests for POP Review

There were two new requests for POP review:

  • Triplet Therapeutics, Inc. v. Board of Supervisors of LSU Agric. and Mech. Coll. (PGR2021-00059) [Notice of Receipt of POP Request issued October 5, 2021] [Petitioner requests review of Institution Decision, presenting the question of whether 35 U.S.C. § 325(d) permits the Board to deny institution of “a written description challenge presented in the petition” which “is [allegedly] the same argument as an enablement rejection raised during prosecution.”]
  • Cisco Sys., Inc. v K.Mizra LLC (IPR2021-00593, -00594) [Notice of Receipt of POP Request issued October 12, 2021] [Patent Owner requests review of Institution Decision, presenting the question of “whether Fintiv factor 2 should compare the proximity of the district court’s trial date to the projected completion of Director review, as opposed to the projected statutory deadline for a final written decision, in light of the Supreme Court’s decision in United States v. Arthrex, Inc., 141 S. Ct. 1970 (2021).”]

Requests for Director Review

  • Parties have submitted 118 requests for Director review under the USPTO’s interim process in light of the Supreme Court’s decision in U.S. v. Arthrex. Of those requests, a total of 51 have been denied, 66 are pending, and one has been withdrawn. No request has been granted.

Authors

More From This Series

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.